WT1 mRNA-loaded autologous monocyte-derived dendritic cells

This investigational autologous dendritic cell (DC) vaccine therapy is being developed by the University Hospital, Antwerp, in collaboration with the University of Antwerp. The therapy involves the collection of a patient's monocytes via apheresis, which are then differentiated into dendritic cells and electroporated with mRNA encoding the Wilms' tumor 1 (WT1) protein. WT1 is a tumor-associated antigen that is frequently overexpressed in pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG). Once administered intradermally, these mature dendritic cells present WT1-derived peptides to the patient's T-cells, aiming to stimulate a robust, tumor-specific immune response. The therapy is currently being evaluated in the Phase I/II ADDICT-pedGLIO trial (NCT04911621) as an adjuvant treatment following or in combination with standard-of-care chemoradiation (temozolomide) to target residual or recurring tumor cells.

Other names

WT1-targeted DC vaccineWT-1-targeted DC vaccineWT 1-targeted DC vaccineautologous WT1 mRNA-loaded DCsWT1 mRNA-electroporated dendritic cellsWT-1 mRNA-electroporated dendritic cellsWT 1 mRNA-electroporated dendritic cellsWT1-loaded DC vaccinationWT-1-loaded DC vaccinationWT 1-loaded DC vaccination